Senate bill would require faster, more transparent prior‑authorization process for Alaska insurers

Senate Bill 133, introduced to the Alaska Senate Labor and Commerce Committee on March 19, would create a statutory prior‑authorization framework for health insurers operating in Alaska, establish specific response timelines and transparency requirements, and grant the Division of Insurance enforcement authority for noncompliance.

The bill requires each health care insurer to designate a prior authorization process that is "reasonable and efficient" and consistent with standards of medical care. Under the bill’s timelines, a standard prior authorization request delivered by methods other than fax must receive a determination within 72 hours; a standard request submitted by fax must be determined within 72 hours excluding weekends; and an expedited request must be decided within 24 hours. If an insurer does not act within those timeframes, the request is considered approved.

The measure would also require insurers to publish their current prior‑authorization standards and documentation requirements on their websites (or portals) and to indicate whether standardized electronic prior authorization is available. If an insurer uses an external utilization review organization (URO), its requirements must be published and, where there is a difference between insurer and URO standards, the more favorable standard to the covered person must apply. A provider may request the qualifications of any peer reviewer who issues an adverse decision.

SB133 would set minimum validity periods for prior authorizations: at least 12 months for chronic conditions while the covered person remains insured, and for other authorizations, 90 calendar days or a clinically appropriate longer period. The bill would require insurers to maintain an application programming interface (API) consistent with Centers for Medicare & Medicaid Services technical standards to automate prior authorization transactions from electronic health record or practice management systems.

The bill includes protections for patients in step‑therapy programs. It would prohibit insurers from mandating step therapy in a way that delays access to an FDA‑approved drug for stage‑4 or advanced metastatic cancer, and it would require an accessible, timely exception process for step‑therapy protocols in other conditions. Providers would still be able to prescribe drugs they consider medically appropriate; insurers and utilization review organizations may request supporting documentation for exception requests.

On enforcement, SB133 would require annual reporting by insurers on compliance with the prior‑authorization provisions and gives the director of the Division of Insurance authority to monitor compliance, initiate examinations at least every two years, and impose penalties for instances of noncompliance. Director Laurie Wing Hyre told the committee the division expects to adopt penalties via regulation and referenced per‑instance fines the division currently uses in market‑conduct enforcement (for example, a range of roughly $250 to $1,000 per instance with higher caps for aggregate enforcement), though final penalty amounts would be set by regulation.

Conrad Jackson, committee staff, said stakeholders — providers, payers and others — worked on the bill over multiple meetings and are in broad agreement on the legislation as drafted, and Director Wing Hyre said the bill reflects a compromise approach that mirrors frameworks other states have adopted. Committee questions focused on enforcement mechanics and the division’s capacity; the director said the division has four investigators for complaint handling and would escalate to market‑conduct examinations where pattern or systemic issues arise.